Summit Therapeutics Past Earnings Performance
Past criteria checks 0/6
Summit Therapeutics's earnings have been declining at an average annual rate of -45.9%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 56.8% per year.
Key information
-45.9%
Earnings growth rate
9.5%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | -56.8% |
| Return on equity | -44.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Summit Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -197 | 58 | 124 |
| 30 Jun 24 | 0 | -162 | 43 | 102 |
| 31 Mar 24 | 0 | -116 | 35 | 80 |
| 31 Dec 23 | 0 | -615 | 30 | 59 |
| 30 Sep 23 | 0 | -598 | 26 | 41 |
| 30 Jun 23 | 0 | -598 | 26 | 43 |
| 31 Mar 23 | 0 | -600 | 27 | 43 |
| 31 Dec 22 | 1 | -79 | 27 | 53 |
| 30 Sep 22 | 1 | -87 | 27 | 70 |
| 30 Jun 22 | 2 | -85 | 27 | 73 |
| 31 Mar 22 | 2 | -93 | 26 | 88 |
| 31 Dec 21 | 2 | -89 | 24 | 85 |
| 30 Sep 21 | 2 | -75 | 19 | 75 |
| 30 Jun 21 | 1 | -73 | 20 | 69 |
| 31 Mar 21 | 1 | -64 | 20 | 59 |
| 31 Dec 20 | 1 | -53 | 19 | 53 |
| 30 Sep 20 | 1 | -51 | 21 | 51 |
| 30 Jun 20 | 1 | -40 | 16 | 47 |
| 31 Mar 20 | -5 | -31 | 13 | 46 |
| 31 Dec 19 | 1 | -32 | 12 | 43 |
| 31 Oct 19 | 26 | -28 | 12 | 44 |
| 31 Jul 19 | 24 | -27 | 12 | 43 |
| 30 Apr 19 | 72 | 12 | 14 | 47 |
| 31 Jan 19 | 57 | 11 | 17 | 52 |
| 31 Oct 18 | 70 | 2 | 18 | 51 |
| 31 Jul 18 | 72 | 11 | 15 | 51 |
| 30 Apr 18 | 27 | -29 | 16 | 49 |
| 31 Jan 18 | 20 | -29 | 17 | 41 |
| 31 Oct 17 | 15 | -18 | 13 | 32 |
| 31 Jul 17 | 12 | -23 | 13 | 27 |
| 30 Apr 17 | 5 | -27 | 12 | 25 |
| 31 Jan 17 | 3 | -27 | 10 | 24 |
| 31 Oct 16 | 1 | -29 | 8 | 23 |
| 31 Jul 16 | 1 | -33 | 8 | 26 |
| 30 Apr 16 | 1 | -32 | 8 | 27 |
| 31 Jan 16 | 2 | -29 | 7 | 24 |
| 31 Oct 15 | 2 | -25 | 7 | 23 |
| 31 Jul 15 | 3 | -20 | 6 | 20 |
| 30 Apr 15 | 3 | -19 | 7 | 17 |
| 31 Jan 15 | 3 | -17 | 6 | 16 |
| 31 Oct 14 | 3 | -17 | 6 | 16 |
| 31 Jul 14 | 4 | -17 | 6 | 16 |
| 30 Apr 14 | 4 | -13 | 4 | 14 |
| 31 Jan 14 | 3 | -10 | 3 | 11 |
Quality Earnings: SMMT * is currently unprofitable.
Growing Profit Margin: SMMT * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMMT * is unprofitable, and losses have increased over the past 5 years at a rate of 45.9% per year.
Accelerating Growth: Unable to compare SMMT *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SMMT * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.6%).
Return on Equity
High ROE: SMMT * has a negative Return on Equity (-44.91%), as it is currently unprofitable.